Notably, in the present study, positive B7-H4 expression was associated with adverse clinical features in ccRCC, which indicated that B7-H4 may be a feasible candidate of choice for RCC-targeted therapy. This evidence concerns the gene VTCN1 and nonpapillary renal cell carcinoma.